THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 108 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $120,725 | -17.9% | 13,989 | -1.5% | 0.00% | 0.0% |
| Q2 2023 | $147,042 | -7.4% | 14,207 | -3.0% | 0.00% | 0.0% |
| Q1 2023 | $158,844 | -12.5% | 14,640 | -9.5% | 0.00% | -50.0% |
| Q4 2022 | $181,472 | +15.6% | 16,174 | +4.3% | 0.00% | 0.0% |
| Q3 2022 | $157,000 | +15.4% | 15,513 | +3.6% | 0.00% | +100.0% |
| Q2 2022 | $136,000 | -4.9% | 14,979 | +0.3% | 0.00% | 0.0% |
| Q1 2022 | $143,000 | -12.8% | 14,941 | +0.7% | 0.00% | 0.0% |
| Q4 2021 | $164,000 | +50.5% | 14,831 | +0.9% | 0.00% | 0.0% |
| Q3 2021 | $109,000 | -38.4% | 14,705 | +20.8% | 0.00% | 0.0% |
| Q2 2021 | $177,000 | -33.5% | 12,174 | -6.6% | 0.00% | -50.0% |
| Q1 2021 | $266,000 | +16.2% | 13,038 | +1.1% | 0.00% | 0.0% |
| Q4 2020 | $229,000 | +16.2% | 12,894 | -3.2% | 0.00% | 0.0% |
| Q3 2020 | $197,000 | -4.8% | 13,325 | +34.9% | 0.00% | -33.3% |
| Q2 2020 | $207,000 | -10.4% | 9,878 | -1.2% | 0.00% | -25.0% |
| Q1 2020 | $231,000 | – | 9,994 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
| Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
| Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
| Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
| Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
| Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
| King Wealth Management Group | 22,500 | $583,000 | 0.15% |
| Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |